| Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis V Makarov, G Manina, K Mikusova, U Möllmann, O Ryabova, ... Science 324 (5928), 801-804, 2009 | 840 | 2009 |
| Towards a new combination therapy for tuberculosis with next generation benzothiazinones V Makarov, B Lechartier, M Zhang, J Neres, AM van der Sar, SA Raadsen, ... EMBO molecular medicine 6 (3), 372-383, 2014 | 399 | 2014 |
| Benzothiazinones: Prodrugs That Covalently Modify the Decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis C Trefzer, M Rengifo-Gonzalez, MJ Hinner, P Schneider, V Makarov, ... Journal of the American Chemical Society 132 (39), 13663-13665, 2010 | 226 | 2010 |
| Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus HC Selinka, L Florin, HD Patel, K Freitag, M Schmidtke, VA Makarov, ... Journal of virology 81 (20), 10970-10980, 2007 | 209 | 2007 |
| Benzothiazinones Are Suicide Inhibitors of Mycobacterial Decaprenylphosphoryl-β-d-ribofuranose 2′-Oxidase DprE1 C Trefzer, H Škovierová, S Buroni, A Bobovská, S Nenci, E Molteni, ... Journal of the American Chemical Society 134 (2), 912-915, 2012 | 203 | 2012 |
| Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones MR Pasca, G Degiacomi, ALJL Ribeiro, F Zara, P De Mori, B Heym, ... Antimicrobial agents and chemotherapy 54 (4), 1616-1618, 2010 | 131 | 2010 |
| 2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 J Neres, RC Hartkoorn, LR Chiarelli, R Gadupudi, MR Pasca, G Mori, ... ACS chemical biology 10 (3), 705-714, 2015 | 126 | 2015 |
| Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients G Degiacomi, JC Sammartino, LR Chiarelli, O Riabova, V Makarov, ... International journal of molecular sciences 20 (23), 5868, 2019 | 116 | 2019 |
| Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance G Manina, M Bellinzoni, MR Pasca, J Neres, A Milano, ... Molecular microbiology 77 (5), 1172-1185, 2010 | 94 | 2010 |
| The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from Mycobacterium tuberculosis V Makarov, J Neres, RC Hartkoorn, OB Ryabova, E Kazakova, M Šarkan, ... Antimicrobial agents and chemotherapy 59 (8), 4446-4452, 2015 | 85 | 2015 |
| Quantitative structure− activity relationship studies of [(Biphenyloxy) propyl] isoxazole derivatives. Inhibitors of human rhinovirus 2 replication VE Kuz'min, AG Artemenko, EN Muratov, IL Volineckaya, VA Makarov, ... Journal of medicinal chemistry 50 (17), 4205-4213, 2007 | 76 | 2007 |
| Discovery of prenylated flavonoids with dual activity against influenza virus and Streptococcus pneumoniae U Grienke, M Richter, E Walther, A Hoffmann, J Kirchmair, V Makarov, ... Scientific Reports 6 (1), 27156, 2016 | 74 | 2016 |
| Thiophenecarboxamide derivatives activated by EthA kill Mycobacterium tuberculosis by inhibiting the CTP synthetase PyrG G Mori, LR Chiarelli, M Esposito, V Makarov, M Bellinzoni, RC Hartkoorn, ... Chemistry & biology 22 (7), 917-927, 2015 | 74 | 2015 |
| Per aspera ad astra: application of Simplex QSAR approach in antiviral research EN Muratov, AG Artemenko, EV Varlamova, PG Polischuk, VP Lozitsky, ... Future medicinal chemistry 2 (7), 1205-1226, 2010 | 73 | 2010 |
| DprE1–from the discovery to the promising tuberculosis drug target K Mikusova, V Makarov, J Neres Current pharmaceutical design 20 (27), 4379-4403, 2014 | 72 | 2014 |
| Optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone macozinone (PBTZ169) A Lupien, A Vocat, CSY Foo, E Blattes, JY Gillon, V Makarov, ST Cole Antimicrobial agents and chemotherapy 62 (11), 10.1128/aac. 00840-18, 2018 | 66 | 2018 |
| New pleconaril and [(biphenyloxy) propyl] isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3 M Schmidtke, P Wutzler, R Zieger, OB Riabova, VA Makarov Antiviral research 81 (1), 56-63, 2009 | 63 | 2009 |
| Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the … M Schmidtke, E Hammerschmidt, S Schüler, R Zell, E Birch-Hirschfeld, ... Journal of Antimicrobial Chemotherapy 56 (4), 648-656, 2005 | 63 | 2005 |
| Novel [(biphenyloxy) propyl] isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication VA Makarov, OB Riabova, VG Granik, P Wutzler, M Schmidtke Journal of Antimicrobial Chemotherapy 55 (4), 483-488, 2005 | 59 | 2005 |
| Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis J Piton, A Vocat, A Lupien, CS Foo, O Riabova, V Makarov, ST Cole Antimicrobial agents and chemotherapy 62 (10), 10.1128/aac. 00681-18, 2018 | 58 | 2018 |
Stewart ColeInstitut PasteurVerified email at pasteur.fr
